Maybe the MHRA are having a hard time justifying paying big bucks for a GBM vaccine that gives 2.8 months longer median survival for newly diagnosed patients and 5.8 months for recurrent patients. Okay, the 13% of long tail patients are fantastic, but is it enough to sway MHRA?
The British economy is in a bad place right now, they are talking about tax hikes to fill the big holes they got.
Market Data 
Markets 
AI
